- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02305134
Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Tipepidine (3-[di-2-thienylmethylene]-1-methylpiperidine) has been used solely as a nonnarcotic antitussive in Japan since 1959. The safety of tipepidine in children and adults has already been established. It is reported that tipepidine inhibits G-protein-coupled inwardly rectifying potassium (GIRK)-channel currents. The inhibition of GIRK channels by tipepidine is expected to modulate the level of monoamines in the brain. We put forward the hypothesis that tipepidine can improve attention deficit/hyperactivity disorder (ADHD) symptoms by modulating monoaminergic neurotransmission through the inhibition of GIRK channels. The purpose of this double-blind, placebo-controlled trial is to confirm whether treatment with tipepidine can improve symptoms in pediatric patients with ADHD.
See our previous open trial, An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD) http://clinicaltrials.gov/show/NCT01835093
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Chuo-ku
-
Chiba, Chuo-ku, Japan, 260-8670
- Department of Psychiatry, Chiba University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
[Inclusion Criteria]
- Diagnosis of attention deficit hyperactivity disorder besed on DSM-5 criteria.
- Scores of 20 or higher in ADHD-RS (physician evaluation) total score.
- currently is an outpatient at Chiba University Hospital Department of Psychiatry or Child Psychiatry.
- currently receiving no medications for ADHD (atomoxetine, methylphenidate) treatment for the previous 4 weeks prior to enrollment in this study.
- currently receiving no medications of antidepressants, mood stabilizers and the antipsychotics treatment for the previous 4 weeks prior to enrollment in this study.
- currently receiving no medications of GIRK channel antagonist (tipepidine, cloperastine, caramiphen) treatment for the previous 4 weeks prior to enrollment in this study.
- Ages 6 - 17, male or female
- Provision of written informed consent by patients and parents or guardian.
- must be able to swallow capsuled medicine.
[Exclusion Criteria]
- History of allergic reaction or hypersensitivity to tipepidine hibenzate.
- Patients who have not been informed of having the disease at the time of informed consent.
- Diagnosis of any of the following diseases based on the DSM-5 criteria. Autism Spectrum Disorder, Schizophrenia Spectrum and Other Psychotic Disorders, Neurocognitive Disorders, Substance Related and Addictive Disorders, Feeding and Eating Disorders, Personality Disorders, Paraphilic Disorders.
- currently receiving medications for ADHD (atomoxetine, methylphenidate) treatment for the previous 4 weeks prior to enrollment in this study.
- currently receiving medications of antidepressants, mood stabilizers and the antipsychotics treatment for the previous 4 weeks prior to enrollment in this study.
- currently receiving medications of GIRK channel antagonist (tipepidine, cloperastine, caramiphen) treatment for the previous 4 weeks prior to enrollment in this study.
- Somatic disorder which requires severe body management or severe meal management.
- participating in another clinical trial within 3 months prior to enrollment into this study. (except for observation study without intervention).
- planning change of treatment because of unstable neurological manifestations or somatic symptoms.
- History of suicidal ideation within the past year.
- pregnant or nursing, or intending to become pregnant or to start breastfeeding during the study.
- Other clinically significant reasons for exclusion by investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Tipepidine Hibenzate
Tipepidine is taken orally at 30 mg/day (10 mg after breakfast, 10 mg after supper, and 10 mg before bedtime), for 4 weeks.
|
|
Placebo Comparator: Placebo
Placebo is taken orally after breakfast, after supper, and before for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The ADHD Rating Scale IV Japanese Version (ADHD-RS-IV-J) by physician.
Time Frame: Changes from baseline in ADHD-RS-IV-J at 4-weeks
|
The ADHD Rating Scale-IV obtains parent ratings regarding the frequency of each ADHD symptom based on DSM-IV criteria.
The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician.
The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items).
|
Changes from baseline in ADHD-RS-IV-J at 4-weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subscores (Inattentive subscore, Hyperactive/impulsive subscore) of the ADHD-RS-IV-J by physician.
Time Frame: Changes from baseline in at 4-weeks
|
Changes from baseline in at 4-weeks
|
|
Total scores and subscores (Inattentive subscore, Hyperactive/impulsive subscore) of the ADHD-RS-IV-J by parents.
Time Frame: Changes from baseline in at 4-weeks
|
Changes from baseline in at 4-weeks
|
|
Total scores and subscores (planning subscore, attention subscore, simultaneous subscore, successive subscore) of DN-CAS (Das-Naglieri Cognitive Assessment System) Japanese Version.
Time Frame: Changes from baseline in at 4-weeks
|
The DN-CAS is an assessment battery designed to evaluate cognitive processing.
It was developed to integrate theoretical and applied areas of psychological knowledge using cognitive processing theory and tests designed to measure-Planning, Attention, Simultaneous, and Successive Processing (PASS)-in individuals ages 5-17.
This assessment facilitates mental health professionals in the identification of Attention-Deficit/Hyperactivity Disorder, Traumatic Brain Injury, learning disabilities, Mental Retardation, and giftedness.
|
Changes from baseline in at 4-weeks
|
Scores of CGI-ADHD-S, CGI-ADHD-I
Time Frame: Changes from baseline in at 4-weeks
|
Changes from baseline in at 4-weeks
|
|
Biologocal markers (Serum levels of Pro-BDNF, Mature-BDNF, Oxytocin)
Time Frame: Changes from baseline in at 4-weeks
|
Changes from baseline in at 4-weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- G26023
- UMIN000015748 (Other Identifier: UMIN Clinical Trials Registry (UMIN-CTR))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit and Disruptive Behavior Disorders
-
National Institute of Mental Health (NIMH)CompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit and Disruptive Behavior DisorderUnited States
-
Baylor College of MedicineCompletedAttention Deficit and Disruptive Behavior Disorders | Attention Deficit Hyperactivity DisorderUnited States
-
Erzurum Regional Training & Research HospitalCompletedAttention Deficit and Disruptive Behavior DisordersTurkey
-
University of PittsburghNational Institute of Mental Health (NIMH); University of Michigan; NYU Langone... and other collaboratorsRecruitingAttention Deficit and Disruptive Behavior Disorders | Child Behavior ProblemUnited States
-
New York UniversityCompletedAttention Deficit Hyperactivity Disorder | Conduct Disorder | Oppositional Defiant Disorder | Disruptive Behavior Disorder | Disruptive BehaviorUnited States
-
Oregon Research InstituteNational Institute on Drug Abuse (NIDA)CompletedAttention Deficit Hyperactivity Disorder | Conduct Disorder | Oppositional Defiant Disorder | Child Disruptive Behavior DisordersUnited States
-
National Institute of Mental Health (NIMH)CompletedAttention Deficit Hyperactivity Disorder | Mood Disorder | Attention Deficit and Disruptive Behavior Disorder | Mental Disorder Diagnosed in ChildhoodUnited States
-
University of South CarolinaUniversity of Georgia; Oregon Research Institute; The University of QueenslandCompletedAttention Deficit Hyperactivity Disorder | Conduct Disorder | Oppositional Defiant Disorder | Childhood Disruptive Behavior Disorders | Parent-Child InteractionsUnited States
-
Tufts Medical CenterNational Institute of Mental Health (NIMH)CompletedAttention Deficit and Disruptive Behavior Disorders | Attention Deficit Disorder With HyperactivityUnited States
-
Centre for Addiction and Mental HealthRecruitingEmotional Disorder | Attention Deficit Hyperactivity Disorder | Conduct Disorder | Oppositional Defiant Disorder | Disruptive Behavior Disorder | Behavioural DisorderCanada
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States